- On 29 July 2026, 10x Genomics announced a multi-year research collaboration with Lausanne University Hospital to apply its Flex Apex and Xenium platforms, with plans to expand to Atera, to study single cell and spatial technologies in cancer diagnostics across several solid tumor types.
- This partnership aims to build a large multimodal dataset linking tumor biology to clinical outcomes, potentially informing future biomarker-driven diagnostics and treatment decision frameworks.
- Now we’ll examine how this clinical collaboration, focused on biomarker discovery and potential diagnostic deployment, interacts with 10x Genomics’ existing investment narrative.
Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
10x Genomics Investment Narrative Recap
To own 10x Genomics, you need to believe its single cell and spatial tools can become core to how clinicians and researchers interrogate complex disease biology, even as the company remains unprofitable and exposed to funding swings in academic and government labs. The new CHUV collaboration supports the diagnostic angle of that thesis, but it does not meaningfully change the near term tension between slowing instrument demand, pricing pressure, and the path toward more stable earnings.
The most relevant recent announcement alongside CHUV is the June 2026 collaboration with Cleveland Clinic, which also applies Flex Apex, Xenium, and a planned Atera rollout to cancer diagnostics, initially in bladder cancer. Taken together, these clinical-facing partnerships show how 10x is trying to build evidence for future biomarker-driven tests while its current financial profile still reflects high R&D intensity, compressed instrument margins, and a forecast that it will remain loss-making for at least three years.
Yet behind the promise of clinical genomics tools, investors should also be aware that...
Read the full narrative on 10x Genomics (it's free!)
10x Genomics’ narrative projects $709.8 million revenue and $110.2 million earnings by 2029.
Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 58% downside to its current price.
Exploring Other Perspectives
Some analysts were already assuming about US$828,000,000 of revenue and US$129,000,000 of earnings by 2029, a far more optimistic view than consensus, and collaborations like CHUV could either reinforce that scenario or highlight how funding risks and competition might justify a more cautious outlook.
Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth as much as 80% more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.
Searching For A Fresh Perspective?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- Uncover the next big thing with 19 elite penny stocks that balance risk and reward.
- Find 51 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com